Enterin | Gut-Brain Axis | Neurodegenerative Disease

Enterin is aiming to become the first company
in the world to develop a novel drug that repairs the dysfunctional
gut-brain axis

in patients with neurodegenerative disease.

Learn More
In preclinical model of Parkinson’s Disease, our lead compound displaces α-synuclein aggregates

and restores normal signaling between the gut and the brain.

Learn More
In December 2018,
we initiated a Phase 2B study of ENT-01

in patients with Parkinson's Disease.

Learn More
We hope that repair of the gut-brain axis is able to significantly improve
quality of life

by influencing multiple non-motor symptoms that affect patients with Parkinson’s Disease and other neurodegenerative conditions.

Learn More
Watch an interview with one of Enterin’s founders, Dr. Michael Zasloff, discussing a new hope
against Parkinson’s,

autism and other neurodegenerative diseases.

WATCH THE VIDEO

Enterin is aiming to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis